Loading...
•
Dec 31, 2020
Protalix Q4 2020 Earnings Report
Protalix reported financial results for the fiscal year ended December 31, 2020, and provided a business update.
Key Takeaways
Protalix BioTherapeutics reported full year 2020 financial results, featuring revenue from selling goods of $16.2 million and revenue from licenses and R&D services of $46.7 million. The company's net loss for the year was $6.5 million, or $0.22 per share.
FDA accepted the BLA for PRX-102 and granted Priority Review designation for PRX-102 for the proposed treatment of adult patients with Fabry disease.
Topline results were positive from the phase III BRIGHT clinical trial.
Final study results from the phase III BRIDGE clinical trial were announced.
The company successfully completed a public offering of its common stock raising gross proceeds of approximately $40.2 million.
Forward Guidance
Protalix anticipates 2021 to be a pivotal year, awaiting the FDA's review of the PRX-102 BLA with a PDUFA date set for April 27, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...